MXPA04002910A - Composicion farmaceutica de liberacion prolongada que contiene metformin. - Google Patents

Composicion farmaceutica de liberacion prolongada que contiene metformin.

Info

Publication number
MXPA04002910A
MXPA04002910A MXPA04002910A MXPA04002910A MXPA04002910A MX PA04002910 A MXPA04002910 A MX PA04002910A MX PA04002910 A MXPA04002910 A MX PA04002910A MX PA04002910 A MXPA04002910 A MX PA04002910A MX PA04002910 A MXPA04002910 A MX PA04002910A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
composition according
cellulose
metformin
water content
Prior art date
Application number
MXPA04002910A
Other languages
English (en)
Spanish (es)
Inventor
Malik Rajiv
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of MXPA04002910A publication Critical patent/MXPA04002910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MXPA04002910A 2001-09-28 2002-09-27 Composicion farmaceutica de liberacion prolongada que contiene metformin. MXPA04002910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1002DE2001 IN192180B (cg-RX-API-DMAC7.html) 2001-09-28 2001-09-28
PCT/IB2002/003997 WO2003028704A1 (en) 2001-09-28 2002-09-27 Extended release pharmaceutical composition containing metformin

Publications (1)

Publication Number Publication Date
MXPA04002910A true MXPA04002910A (es) 2004-07-05

Family

ID=11097117

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002910A MXPA04002910A (es) 2001-09-28 2002-09-27 Composicion farmaceutica de liberacion prolongada que contiene metformin.

Country Status (12)

Country Link
US (1) US20040059001A1 (cg-RX-API-DMAC7.html)
EP (1) EP1434568A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005507896A (cg-RX-API-DMAC7.html)
KR (1) KR20040063900A (cg-RX-API-DMAC7.html)
CN (1) CN1582145A (cg-RX-API-DMAC7.html)
AR (1) AR037326A1 (cg-RX-API-DMAC7.html)
BR (1) BR0212931A (cg-RX-API-DMAC7.html)
EA (1) EA200400487A1 (cg-RX-API-DMAC7.html)
IN (1) IN192180B (cg-RX-API-DMAC7.html)
MX (1) MXPA04002910A (cg-RX-API-DMAC7.html)
WO (1) WO2003028704A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200402532B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100897890B1 (ko) * 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
CN1805738A (zh) * 2003-06-16 2006-07-19 兰贝克赛实验室有限公司 持续释放的二甲双胍片剂
WO2005092293A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Formulations of metformin
US20060088594A1 (en) * 2004-10-08 2006-04-27 Pilgaonkar Pratibha S Highly compressible controlled delivery compositions of metformin
EP2283811A1 (en) * 2004-10-19 2011-02-16 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil hydrochloride
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
AU2006244213B2 (en) * 2005-05-10 2010-05-13 Novartis Ag Extrusion process for making compositions with poorly compressible therapeutic compounds
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
EP1942872A2 (en) * 2005-11-04 2008-07-16 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
BRPI0605967A (pt) * 2006-12-20 2008-08-12 Medley S A Ind Farmaceutica composição farmacêutica de liberação controlada, forma farmacêutica de liberação controlada e processo para obtenção de forma farmacêutica
CN105152983A (zh) * 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
CN106138020A (zh) * 2015-04-03 2016-11-23 中国人民解放军第三军医大学第三附属医院 双胍类药物在制备预防或减弱肺纤维化的药物中的应用
CN107049980A (zh) * 2017-04-01 2017-08-18 重庆康刻尔制药有限公司 一种盐酸二甲双胍缓释片及其制备方法
WO2021133046A1 (ko) * 2019-12-23 2021-07-01 주식회사 대웅제약 메트포르민 서방성 제제 및 이의 제조 방법
CN111588701B (zh) * 2020-05-25 2021-04-23 上海普康药业有限公司 一种盐酸二甲双胍缓释片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
KR100620935B1 (ko) * 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets

Also Published As

Publication number Publication date
WO2003028704A1 (en) 2003-04-10
ZA200402532B (en) 2005-01-04
JP2005507896A (ja) 2005-03-24
EP1434568A1 (en) 2004-07-07
KR20040063900A (ko) 2004-07-14
BR0212931A (pt) 2004-10-13
IN192180B (cg-RX-API-DMAC7.html) 2004-03-06
US20040059001A1 (en) 2004-03-25
AR037326A1 (es) 2004-11-03
CN1582145A (zh) 2005-02-16
EA200400487A1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
MXPA04002910A (es) Composicion farmaceutica de liberacion prolongada que contiene metformin.
JP4084309B2 (ja) 単一の結晶形を含有する固形製剤
EP0487774B1 (en) A direct tabletting auxiliary
US20060165779A1 (en) Novel method stabilizing bupropion hydrochloride tablets
CA2572729A1 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP2014012747A (ja) バルサルタンの固体経口剤形
EP1646374A1 (en) Extended-release tablets of metformin
CA2415131A1 (en) Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
EA006008B1 (ru) Способ получения таблеток из фармацевтически активных веществ
CN105456222A (zh) 马来酸阿法替尼片及其制备方法
JPH04128221A (ja) 鎮痛剤組成物およびその組成方法
KR101033975B1 (ko) 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
EP2379061B1 (en) Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
JP4370050B2 (ja) クラリスロマイシン錠剤およびその製造法
WO2019012552A4 (en) Compositions of ferric organic compounds
KR101817714B1 (ko) 발사르탄을 포함하는 경구용 고형 제제
CA2532714C (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
AU2002334326A1 (en) Extended release pharmaceutical composition containing metformin
KR100471941B1 (ko) 고형 약제 및 그의 제조 방법
WO2007026261A2 (en) Formulations containing losartan and/or its salts
JP2004352633A (ja) 酸化マグネシウム錠剤
WO2024121413A1 (en) Formulation comprising edoxaban and preparation thereof
CN117919186A (zh) 一种甲磺酸沙芬酰胺片及其制备方法
CN121240854A (zh) 包含具有G12C突变的k-Ras蛋白的抑制剂的固体调配物以及制备方法
WO2007047040A2 (en) Directly compressible extended release alprazolam formulation